AcelRx Pharmaceuticals Inc. has been awarded a $5.6 million grant by the U.S. Army Medical Research and Material Command for development of a new pain treatment.
The grant will reimburse Redwood City-based AcelRx (NASDAQ: ACRX) for manufacturing and clinical costs needed for the planned Phase 2 trial of the new drug, ARX-04, and preparation for Phase 3 development.
No comments:
Post a Comment